KPTIのチャート
KPTIの企業情報
| symbol | KPTI |
|---|---|
| 会社名 | Karyopharm Therapeutics Inc （カリョファ―ム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 カリオファーム・セラピューティクス（Karyopharm Therapeutics Inc.）は臨床段階の製薬会社である。同社はその他の主要疾患と癌の治療用核輸送と関連ターゲットに対する薬物の発見・開発・商業化に焦点を当てる。同社は核輸出タンパク質XPO1を阻害する化合物、核輸出の選択的阻害剤（SINE）及び小分子を発見・開発する。同社の薬物候補であるセリネクサー（KPT-330）は前処理再発性のがん徴候の治療のための経口投与剤である。同社はまた固形腫瘍適応症におけるセリクソーの臨床開発に従事する。口腔セリソクサーは再発性・難治性血液学と固形腫瘍の悪性腫瘍患者に行われる複数の後期臨床試験で評価される。リード薬候補である口腔セリソクサー（KPT-330）、verdinexor（KPT-335）、KPT-8602およびKPT-9274は臨床開発中である。 カリョファ―ム・セラピュ―ティクスは米国の製薬会社。がんや他の主要疾患の新治療薬の発見・開発に従事。主な製品候補には、臨床段階の多発性骨髄腫治療薬「セリネクソ―ル」がある。また、白血病などの治療薬候補も保有。同社は2008年に設立し、マサチュ―セッツ州に本社を置く。 Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for NEXPOVIO® (selinexor) for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. |
| 本社所在地 | 85 Wells Avenue 2nd Floor Newton MA 02459 USA |
| 代表者氏名 | Sharon Shacham シャロン・シャチャム |
| 代表者役職名 | President Co-Founder Chief Scientific Officer |
| 電話番号 | +1 617-658-0600 |
| 設立年月日 | 39783 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 154人 |
| url | www.karyopharm.com |
| nasdaq_url | https://www.nasdaq.com/symbol/kpti |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -143.07800 |
| 終値（lastsale） | 15.55 |
| 時価総額（marketcap） | 941761631.95 |
| 時価総額 | 時価総額（百万ドル） 743.11350 |
| 売上高 | 売上高（百万ドル） 31.42500 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 501.99250 |
| 当期純利益 | 当期純利益（百万ドル） -141.79400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Karyopharm Therapeutics Inc revenues increased from $71K to $29.9M. Net loss increased 22% to $72.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development increase of 82% to $86.1M (expense) General and Administrative increase of 33% to $17.1M (expense). |
KPTIのテクニカル分析
KPTIのニュース
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) stock crossing the finish line today 2023/02/21 17:48:00 US Post News
Karyopharm Therapeutics Inc. (KPTI)’s stock has witnessed a price declined of -5.63% from the previous close with its current price standing at $3.35. Its current price is -77.26% under its 52-week high of $14.73 and 36.73% more than its 52-week low of $2.45. Based on the past 30-day period, the stock price is -12.53% below […]
Let’s Start With The Stock Forecast For Karyopharm Therapeutics Inc. (NASDAQ: KPTI) 2023/02/21 13:00:00 Marketing Sentinel
In the last trading session, 1.67 million Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares changed hands as the company’s beta touched 0.02. With the company’s per share price at $3.55 changed hands at -$0.04 or -1.11% during last session, the market valuation stood at $406.40M. KPTI’s last price was a discount, traded about -314.93% off its 52-week … Let’s Start With The Stock Forecast For Karyopharm Therapeutics Inc. (NASDAQ: KPTI) Read More »
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy 2023/02/21 13:00:00 PR Newswire
Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indication NEWTON, Mass. and FLORENCE, Italy, Feb. 21, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer…
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy 2023/02/21 13:00:00 Karyopharm Therapeutics
Karyopharm Therapeutics (KPTI) Q4 2022 Earnings Call Transcript 2023/02/15 19:00:37 The Motley Fool
KPTI earnings call for the period ending December 31, 2022.
KPTI stock gains as company wins FDA’s Orphan Drug status for cancer drug (NASDAQ:KPTI) 2022/05/26 17:04:53 Seeking Alpha
The U.S. Food and Drug Administration ((FDA)) on Thursday granted its Orphan Drug Designation for Karyopharm Therapeutics (KPTI) for the company’s leading product, selinexor…
Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma 2022/05/25 12:35:58 Seeking Alpha
Karyopharm Therapeutics (KPTI) and the European Myeloma Network ((EMN)), a collaboration of centers for multiple myeloma in Europe and Australia, said the first patient was dosed in…
Earnings Scheduled For May 5, 2022 2022/05/05 08:43:22 Benzinga
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ: MIRM ) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. • Bluegreen Vacations (NYSE: BVH ) is estimated to report quarterly earnings at $0.53 per share on revenue of $181.17 million. • Selecta Biosciences (NASDAQ: SELB ) is expected to report quarterly loss at $0.11 per share on revenue of $13.12 million. • Alpha Metallurgical (NYSE: AMR ) is projected to report quarterly earnings at $19.04 per share on revenue of $944.95 million. • DigitalBridge Group (NYSE: DBRG ) is projected to report quarterly loss at $0.03 per share on revenue of $259.60 million. • Madison Square Garden (NYSE: MSGS ) is projected to report quarterly earnings at $1.59 per share on revenue of $332.95 million. • Intellia Therapeutics (NASDAQ: NTLA ) is likely to report quarterly loss at $1.10 per share on revenue of $8.54 million. • InterDigital (NASDAQ: IDCC ) is estimated to report quarterly earnings at $0.73 per share on revenue of $97.
FY2021 EPS Estimates for Karyopharm Therapeutics Inc. Boosted by Wedbush (NASDAQ:KPTI) 2021/12/24 11:58:41 Transcript Daily
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Investment analysts at Wedbush upped their FY2021 earnings per share (EPS) estimates for shares of Karyopharm Therapeutics in a note issued to investors on Tuesday, December 21st. Wedbush analyst D. Nierengarten now expects that the company will earn ($1.81) per share for the year, up from their prior estimate of []
Karyopharm, Menarini Ink Over $200M Licensing Pact For Selinexor In Europe, Other Territories 2021/12/21 20:09:57 Benzinga
Karyopharm Therapeutics Inc (NASDAQ: KPTI ) and the Menarini Group entered an exclusive licensing agreement whereby Menarini will commercialize Karyopharm''s Nexpovio (selinexor) in Europe and other key global territories. Under the agreement terms, Menarini received exclusive rights to commercialize Nexpovio for oncology indications in the European Union and other European countries, Latin America Full story available on Benzinga.com
Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? 2021/12/21 18:00:00 Stocks Register
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded at $6.47 at last check on Tuesday, December 21, made an upward move of 1.65% on its previous day’s price. Looking at the stock we see that its previous close was $6.36 and the beta (5Y monthly) reads 0.20 with the day’s price range being $5.88 – $6.48. In terms … Is Karyopharm Therapeutics Inc. (NASDAQ: KPTI) A Great Stock To Invest In? Read More »
Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win 2021/12/21 13:30:00 Marketing Sentinel
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has a beta value of -0.03 and has seen 1.79 million shares traded in the last trading session. The company, currently valued at $468.80M, closed the last trade at $6.36 per share which meant it gained $0.21 on the day or 3.41% during that session. The KPTI stock price is -183.02% … Karyopharm Therapeutics Inc. (KPTI) Gains 3.41%, Causing Bears To Win Read More »
Brokerages Expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Will Post Quarterly Sales of $29.61 Million 2021/12/20 09:20:41 Dakota Financial News
Brokerages expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to announce sales of $29.61 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Karyopharm Therapeutics earnings, with the lowest sales estimate coming in at $24.30 million and the highest estimate coming in at $38.69 million. Karyopharm Therapeutics posted sales of $35.10 million []